432 related articles for article (PubMed ID: 30293116)
1. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
Singh YP; Pandey A; Vishwakarma S; Modi G
Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
[TBL] [Abstract][Full Text] [Related]
2. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
3. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders.
Gassen M; Youdim MB
Pharmacol Toxicol; 1997 Apr; 80(4):159-66. PubMed ID: 9140134
[TBL] [Abstract][Full Text] [Related]
4. Neurodegenerative diseases and therapeutic strategies using iron chelators.
Ward RJ; Dexter DT; Crichton RR
J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
[TBL] [Abstract][Full Text] [Related]
5. Iron in neurodegenerative disorders: being in the wrong place at the wrong time?
Apostolakis S; Kypraiou AM
Rev Neurosci; 2017 Nov; 28(8):893-911. PubMed ID: 28792913
[TBL] [Abstract][Full Text] [Related]
6. Iron and Parkinson's disease: chelators to the rescue?
Levenson CW
Nutr Rev; 2003 Sep; 61(9):311-3. PubMed ID: 14552066
[TBL] [Abstract][Full Text] [Related]
7. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
[TBL] [Abstract][Full Text] [Related]
9. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators.
Amit T; Avramovich-Tirosh Y; Youdim MB; Mandel S
FASEB J; 2008 May; 22(5):1296-305. PubMed ID: 18048580
[TBL] [Abstract][Full Text] [Related]
10. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.
Weinreb O; Mandel S; Youdim MBH; Amit T
Free Radic Biol Med; 2013 Sep; 62():52-64. PubMed ID: 23376471
[TBL] [Abstract][Full Text] [Related]
11. The role of iron in brain ageing and neurodegenerative disorders.
Ward RJ; Zucca FA; Duyn JH; Crichton RR; Zecca L
Lancet Neurol; 2014 Oct; 13(10):1045-60. PubMed ID: 25231526
[TBL] [Abstract][Full Text] [Related]
12. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.
Belaidi AA; Bush AI
J Neurochem; 2016 Oct; 139 Suppl 1():179-197. PubMed ID: 26545340
[TBL] [Abstract][Full Text] [Related]
13. New therapeutic strategy for Parkinson's and Alzheimer's disease.
Esposito E; Cuzzocrea S
Curr Med Chem; 2010; 17(25):2764-74. PubMed ID: 20586718
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
Beal MF
J Bioenerg Biomembr; 2004 Aug; 36(4):381-6. PubMed ID: 15377876
[TBL] [Abstract][Full Text] [Related]
15. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
Hölscher C
Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
[TBL] [Abstract][Full Text] [Related]
16. Iron chelation and neuroprotection in neurodegenerative diseases.
Li X; Jankovic J; Le W
J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
[TBL] [Abstract][Full Text] [Related]
17. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
[TBL] [Abstract][Full Text] [Related]
18. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging.
Bar-Am O; Amit T; Kupershmidt L; Aluf Y; Mechlovich D; Kabha H; Danovitch L; Zurawski VR; Youdim MB; Weinreb O
Neurobiol Aging; 2015 Mar; 36(3):1529-42. PubMed ID: 25499799
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway.
Weinreb O; Amit T; Mandel S; Youdim MB
Neurodegener Dis; 2012; 10(1-4):112-5. PubMed ID: 22156453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
